Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Inhibitory Control Training in Eating Behaviors

NCT03599115
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Inhibitory Control Training
Behavioral
Lead sponsor
Brigham Young University
Other
Eligibility
18 Years to 45 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

TMS for Improving Response Inhibition in Adolescents With OCD

NCT05104697
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Bradley Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Riverside, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

NCT00124189
View directory record Official record
Conditions
Chronic Lymphoproliferative Diseases
Interventions
GRN163L
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
8
States / cities
Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 19, 2026, 9:03 PM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 9:03 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03455764
View directory record Official record
Conditions
Melanoma
Interventions
MCS110, Dabrafenib, Trametinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

NCT01265953
View directory record Official record
Conditions
Prostate Cancer Prevention
Interventions
SFN-rich broccoli sprout extract capsules, Gelatin capsule containing microcrystalline cellulose.
Drug · Dietary Supplement
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
21 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT04034485
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
lerodalcibep, evolocumab
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 19, 2026, 9:03 PM EDT
Not listed Phase 4 Interventional

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

NCT00673218
View directory record Official record
Conditions
Allergy
Interventions
Placebo, Xolair
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 19, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

IL1 Inhibition in FOP

NCT06724562
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Anti-IL1 Therapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 4 Interventional

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

NCT00347503
View directory record Official record
Conditions
Cataract
Interventions
ketorolac 0.4%, bromfenac 0.09%
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2007 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

NCT00702403
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Positive Adult Acute Lymphoblastic Leukemia, Philadelphia Positive Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Relapsing Chronic Myelogenous Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
nilotinib, imatinib mesylate, pharmacological study
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Stanford, California • Tampa, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 19, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

NCT06918132
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 9:03 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

NCT01968655
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

NCT06123026
View directory record Official record
Conditions
Lactation Suppressed, Second Trimester Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Tadalafil in Becker Muscular Dystrophy

NCT01070511
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prostaglandin Inhibition for Emphysema

NCT02006576
View directory record Official record
Conditions
Emphysema
Interventions
600 mg ibuprofen three times daily for 48 weeks, Placebo three times daily
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
46 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI

NCT02307526
View directory record Official record
Conditions
Hypotension, Postural
Interventions
Pyridostigmine Bromide, Tilt table test
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 19, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NCT04949113
View directory record Official record
Conditions
Malignant Melanoma Stage III
Interventions
Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
Drug
Lead sponsor
The Netherlands Cancer Institute
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 19, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

NCT06843551
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Benjamin Spieler
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

NCT00104572
View directory record Official record
Conditions
Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions
Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU
Drug · Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

NCT03012230
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Ruxolitinib Phosphate
Other · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 19, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Neurobehavioral Affective Control Training

NCT06226467
View directory record Official record
Conditions
Emotional Distress, Impulsive Behavior, Mood Lability, Mood Instability, Rumination, Psychopathology, Affective Symptoms
Interventions
Neurobehavioral Affective Control Training
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 19, 2026, 9:03 PM EDT